The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
about
Insulin-like growth factors in the gastrointestinal tract and liverChanges in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityInterdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral NutritionDynamic functional modules in co-expressed protein interaction networks of dilated cardiomyopathy.Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure.Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs.IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestineProtracted upregulation of leptin and IGF1 is associated with activation of PI3K/Akt and JAK2 pathway in mouse intestine after ionizing radiation exposure.Emerging treatment options for short bowel syndrome: potential role of teduglutideGlucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway.Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity.Exogenous GLP-2 and IGF-I induce a differential intestinal response in IGF binding protein-3 and -5 double knockout miceIntestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsIrinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritisGlucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.High-protein diet improves postoperative weight gain after massive small-bowel resection.Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.Space radiation exposure persistently increased leptin and IGF1 in serum and activated leptin-IGF1 signaling axis in mouse intestineOvernutrition stimulates intestinal epithelium proliferation through β-catenin signaling in obese mice.Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed ratsEnteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.The "cryptic" mechanism of action of glucagon-like peptide-2.Nonruminant Nutrition Symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander?Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.Review article: a comparison of glucagon-like peptides 1 and 2.The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.Differential Effects on Intestinal Adaptation Following Exogenous Glucagon-Like Peptide 2 Therapy With and Without Enteral Nutrition in Neonatal Short Bowel Syndrome [Formula: see text].Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.The endogenous preproglucagon system is not essential for gut growth homeostasis in miceEffects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in ratsGlucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.
P2860
Q26998926-735DF0D7-3567-4C42-A547-BE7913B36652Q29617378-CE605860-1106-4B27-94DF-8AFC663637E7Q33600424-8FFC60BE-67B2-4989-A100-3D7DCCBB536BQ33719832-3FEA0A07-CED2-43A0-AC11-CCC915DE5BABQ34425937-6C859639-5ECB-4ADA-92BC-0C8441A5BB1CQ34726758-4374A926-EE77-451D-A2BD-34632EB6090DQ34980692-0FCF1747-7C08-408D-B123-37510F897460Q34982361-5646D2D0-B5F0-459F-B189-29911A1401ADQ35069195-94B6D44F-AC02-444F-985D-72DA11193421Q35304614-E9355D4E-A028-4504-AEEE-00ABE466B052Q35756432-E5ED56A2-22C8-4A19-B528-FDE45560114BQ35880172-707437CC-F7C6-4C7D-B134-0A9762C12EB1Q35970167-2EBA7A5E-2AA7-4A17-ACCD-B06376686B01Q35986076-94164736-7330-42DF-BCBE-CF73B93CC52FQ36063090-85F58FD8-8377-4517-8212-2897501D287CQ36171894-0940AF57-7D1D-47C1-835D-62D9E95C00C5Q36309586-0B81A067-D261-40DF-8A73-DFCD5CDD6FAAQ36710034-EC15417C-909C-40B9-80C7-C04A30AE916CQ36710038-A98D0548-C6E5-4FAA-B81B-51DA403A31DEQ37136193-BD48C827-3BDB-4615-81A9-B65C72F4A02FQ37138788-0F4BD768-C362-4AF7-9402-8CC106746466Q37200132-4D539709-5737-4014-95E6-2086D1D39AC7Q37202378-DC751AF2-2FDC-41AF-8A25-55129F518247Q37251157-747E29D6-88FA-4726-9C5E-6CEEA65530B1Q37422061-E06AF647-B0A4-4B37-8453-139C42232C46Q37662980-DD5FB07A-D9FA-4024-9C0B-C7440AEB1D3BQ37870031-F981F6AA-0EFB-409D-992C-9A06DB448D45Q37958506-48C4CDB0-6FF7-4D1C-BE77-40DA082DE5ABQ37975414-643AC62E-CAC6-42E3-9358-B53B8BCD127EQ38048602-F65F36D0-1A63-4E04-AA7B-3D57AE077815Q38057350-ABCBECEA-DBF2-460A-9CB1-E9530EE63FF5Q38101129-E191BB95-27C2-4205-B4F3-3AFFCFA6D2A7Q38711705-5B6D130F-73ED-47CE-A80F-D052BB022B0FQ39359573-7E2C6500-4C3E-4B61-B81F-8415DA69269DQ39974508-FDA1BD2A-FF27-4089-977E-57EA0AF390EAQ40074896-D2BB5C22-8745-4E35-9FB2-0F912CE1A809Q40116671-1112A7EB-039A-4550-9731-6742663F58A7Q41038731-E1ACBFD4-A127-4269-9189-5391F087A3D4Q41106209-93D8EAA8-4778-4EAD-B73F-2113DC239700Q41393541-83F4AA0B-6E6B-44C7-9F18-3FF6E035A665
P2860
The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The essential role of insulin- ...... ucagon-like peptide-2 in mice.
@en
type
label
The essential role of insulin- ...... ucagon-like peptide-2 in mice.
@en
prefLabel
The essential role of insulin- ...... ucagon-like peptide-2 in mice.
@en
P2093
P1433
P1476
The essential role of insulin- ...... ucagon-like peptide-2 in mice.
@en
P2093
Catherine L Forse
Jasmine Bahrami
Patricia L Brubaker
Philip E Dubé
P304
P356
10.1053/J.GASTRO.2006.05.055
P407
P577
2006-08-01T00:00:00Z